

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAPLUS
NEWS	23	May 27	CAPLUS super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004
NEWS EXPRESS		MARCH 31	CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:16:02 ON 17 JUN 2004

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 16:16:25 ON 17 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:16:25 ON 17 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:16:25 ON 17 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s implant? and device
L1 189288 IMPLANT? AND DEVICE

=> s l1 and (drug delivery)
2 FILES SEARCHED...
L2 10581 L1 AND (DRUG DELIVERY)

=> s l2 and coat?
L3 6970 L2 AND COAT?

=> s l3 and barrier
L4 2673 L3 AND BARRIER

=> s l4 and biodegradable
L5 1182 L4 AND BIODEGRADABLE

=> s l5 and (rate control?)
L6 147 L5 AND (RATE CONTROL?)

=> s l6 and layer?
L7 131 L6 AND LAYER?

=> s l7 and substrate
L8 67 L7 AND SUBSTRATE

=> s l8 and (stent or graft or catheter or balloon)
L9 51 L8 AND (STENT OR GRAFT OR CATHETER OR BALLOON)

=> s l9 and uniform
L10 9 L9 AND UNIFORM

=> d l10 1-9 ibib abs

L10 ANSWER 1 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:95568 USPATFULL
TITLE: Phosphorus-containing compounds and uses thereof
INVENTOR(S): Metcalf, Chester A., III, Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Berstein, David L., Waban, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004073024	A1	20040415
APPLICATION INFO.:	US 2003-635054	A1	20030806 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-357152, filed on 3 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353252P	20020201 (60)
	US 2002-426928P	20021115 (60)
	US 2002-428383P	20021122 (60)
	US 2002-433930P	20021217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3658	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns a new family of phosphorus-containing compounds containing a moiety JQA- in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a bond linking a R.sup.5 moiety to P;

each occurrence of R and R is independently an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or H; and

each occurrence of R.sup.6 is independently --PK(YR.sup.5)(YR.sup.5), --SO.sub.2(YR.sup.5) or --C(O)(YR.sup.5); so long as any R or R.sup.5 moiety linked directly to P is not H;

wherein two R.sup.2, R.sup.5 and/or R.sup.6 moieties may be chemically linked to one another to form a ring;

each occurrence of G is independently --O--, --S--, --NR.sup.2-- or (M).sub.x;

each occurrence of M is independently a substituted or unsubstituted methylene moiety, and any M-M' moiety may be saturated or unsaturated;

each occurrence of x is independently an integer from 1-6; and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:312692 USPATFULL
TITLE: Phosphorus-containing compounds and uses thereof
INVENTOR(S): Berstein, David L., Waban, MA, UNITED STATES
Metcalf, Chester A., III, Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003220297	A1	20031127
APPLICATION INFO.:	US 2003-357152	A1	20030203 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353252P	20020201 (60)
	US 2002-426928P	20021115 (60)
	US 2002-428383P	20021122 (60)
	US 2002-433930P	20021217 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David L. Berstein, ARIAD Gene Therapeutics, Inc., 26
Landsdowne Street, Cambridge, MA, 02139-4234

NUMBER OF CLAIMS: 39

EXEMPLARY CLAIM: 1

LINE COUNT: 3696

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns a new family of phosphorus-containing compounds containing a moiety JQA--in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a chemical bond linking a R.sup.5 moiety to P;

and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:311966 USPATFULL
TITLE: Polymer **coating** for medical devices
INVENTOR(S): Rypacek, Frantisek, Prague, CZECH REPUBLIC
Lapcikova, Monika, Prague, CZECH REPUBLIC
Machova, Ludka, Prague, CZECH REPUBLIC

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219562	A1	20031127
APPLICATION INFO.:	US 2003-366767	A1	20030214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-357573P	20020215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606

NUMBER OF CLAIMS: 51

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 2870

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Coatings** are provided in which surfaces may be activated by covalently bonding a silane derivative to the metal surface, covalently bonding a lactone polymer to the silane derivative by in situ ring opening polymerization, and depositing at least one **layer** of a polyester on the bonded lactone. Biologically active agents may be deposited with the polyester **layers**. Such **coated** surfaces may be useful in medical devices, in particular stents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:121162 USPATFULL

TITLE: Apparatus and methods for variably controlled substance delivery from **implanted** prostheses

INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES

Yan, John, Los Gatos, CA, UNITED STATES

PATENT ASSIGNEE(S): AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083646	A1	20030501
APPLICATION INFO.:	US 2001-17500	A1	20011214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	112		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	2731		

AB The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides luminal prostheses which allow for a programmed and controlled substance delivery protocols for a variety of purposes. The prostheses comprise a scaffold which is **implantable** within a body lumen and a substance reservoir present over at least a portion of the scaffold. Usually, a **rate-controlling** element will be formed over the substance-containing reservoir to provide for a number of different substance release characteristics.

L10 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:93678 USPATFULL

TITLE: Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

INVENTOR(S): Kharazmi, Arsalan, Hellerup, DENMARK
Christensen, Soren Brogger, Nivaa, DENMARK

Nielsen, Simon Feldbaek, Herlev, DENMARK
PATENT ASSIGNEE(S): Statens Serum Institute, Copenhagen K, DENMARK (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003065039 A1 20030403
APPLICATION INFO.: US 2002-62208 A1 20020131 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-462125, filed on 27 Dec
1999, PENDING A 371 of International Ser. No. WO
1998-DK283, filed on 26 Jun 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1997-762	19970626
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,, INTELLECTUAL PROPERTY PRACTICE GROUP, EDWARDS & ANGELL, LLP., P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	335	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	37 Drawing Page(s)	
LINE COUNT:	7715	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:4518 USPATFULL
TITLE: **Drug delivery** platform
INVENTOR(S): Elkins, Christopher J., Redwood City, CA, UNITED STATES
Dake, Michael D., Stanford, CA, UNITED STATES
Waugh, Jacob M., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004564	A1	20030102
APPLICATION INFO.:	US 2002-101455	A1	20020311 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-285383P	20010420 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	1700	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **stent** based **drug delivery** system. A biological agent of interest is entrapped within a matrix, which is loaded into channels on the surface of a **stent**. The matrix

allows for release, usually sustained release, of the entrapped agent. The **stent** and matrix is sheathed with a covalently bound gel. In one embodiment of the invention, the **stent** is used to deliver therapeutic agents to a patient, providing the advantage of efficient delivery and sustained release of an agent at a localized site. In another embodiment of the invention, the **drug delivery** system is used for testing and comparison of candidate drugs in an in vivo setting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:198316 USPATFULL

TITLE: **Drug delivery** devices comprising **biodegradable** protein for the controlled release of pharmacologically active agents and method of making the **drug delivery** devices

INVENTOR(S): Masters, David B., Hastings, MN, UNITED STATES

PATENT ASSIGNEE(S): Gel-Del Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106410	A1	20020808
APPLICATION INFO.:	US 2001-14947	A1	20011211 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-160421, filed on 25 Sep 1998, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60048P	19970925 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John F. Dolan, Fredrikson & Byron, P.A., 1100 International Centre, 900 Second Avenue South, Minneapolis, MN, 55408-3397	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1828	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method of making **drug delivery** devices for the controlled release of pharmacologically active agents and further, to **drug delivery** devices made by such method. More specifically, the present invention relates to a method of forming a film comprising one or more **biodegradable** polymeric materials, one or more pharmacologically active agents, and one or more biocompatible solvents. The film is then partially dried, rolled or otherwise shaped, and then compressed. In this manner, the amount of pharmacologically active agent(s) that can be incorporated into the **drug delivery device** is increased and the pharmacologically active agent(s) is/are substantially homogeneously distributed throughout the **drug delivery device**. As a result, the release characteristics of the pharmacologically active agent from the **drug delivery device** are enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:48052 USPATFULL

TITLE: Protein matrix materials, devices and methods of making and using thereof

INVENTOR(S): Masters, David B., Hastings, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002028243	A1	20020307
APPLICATION INFO.:	US 2001-796170	A1	20010228 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-160421, filed on 25 Sep 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-185420P	20000228 (60)
	US 2000-222762P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John F. Dolan, Fredrikson & Byron, P.A., 1100 International Center, 900 Second Avenue South, Minneapolis, MN, 55402	
NUMBER OF CLAIMS:	89	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Page(s)	
LINE COUNT:	3903	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, **drug delivery** devices for the controlled release of pharmacologically active agents, encapsulated or **coated stent** devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more **biodegradable** protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix **device**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2002:19086 USPATFULL
 TITLE: **Drug delivery** devices comprising **biodegradable** protein for the controlled release of pharmacologically active agents and method of making the **drug delivery** devices
 INVENTOR(S): Masters, David B., Hastings, MN, United States
 PATENT ASSIGNEE(S): Gel-Del Technologies, Inc., Saint Paul, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342250	B1	20020129
APPLICATION INFO.:	US 1998-160421		19980925 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60048P	19970925 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Webman, Edward J.	
LEGAL REPRESENTATIVE:	Fredrikson & Byron, PA	
NUMBER OF CLAIMS:	33	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1740

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method of making **drug delivery** devices for the controlled release of pharmacologically active agents and further, to **drug delivery** devices made by such method. More specifically, the present invention relates to a method of forming a film comprising one or more **biodegradable** polymeric materials, one or more pharmacologically active agents, and one or more biocompatible solvents. The film is then partially dried, rolled or otherwise shaped, and then compressed. In this manner, the amount of pharmacologically active agent(s) that can be incorporated into the **drug delivery device** is increased and the pharmacologically active agent(s) is/are substantially homogeneously distributed throughout the **drug delivery device**. As a result, the release characteristics of the pharmacologically active agent from the **drug delivery device** are enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:16:02 ON 17 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 16:16:25 ON 17 JUN 2004

L1 189288 S IMPLANT? AND DEVICE
L2 10581 S L1 AND (DRUG DELIVERY)
L3 6970 S L2 AND COAT?
L4 2673 S L3 AND BARRIER
L5 1182 S L4 AND BIODEGRADABLE
L6 147 S L5 AND (RATE CONTROL?)
L7 131 S L6 AND LAYER?
L8 67 S L7 AND SUBSTRATE
L9 51 S L8 AND (STENT OR GRAFT OR CATHETER OR BALLOON)
L10 9 S L9 AND UNIFORM

=> s l9 and discrete

L11 29 L9 AND DISCRETE

=> d L11 1-29 ibib abs

L11 ANSWER 1 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2004:139369 USPATFULL

TITLE: Compounds and methods for modulating cell adhesion

INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA

Gour, Barbara J., Kemptville, CANADA

Farookhi, Riaz, Montreal, CANADA

Ali, Anmar, San Diego, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2004106545 A1 20040603
APPLICATION INFO.: US 2003-632678 A1 20030801 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-464071, filed
on 18 Jun 2003, PENDING Continuation of Ser. No. US
2000-544782, filed on 7 Apr 2000, GRANTED, Pat. No. US
6610821 Continuation-in-part of Ser. No. US
1999-458870, filed on 10 Dec 1999, GRANTED, Pat. No. US
6465427 Continuation-in-part of Ser. No. US
1999-357717, filed on 20 Jul 1999, GRANTED, Pat. No. US

6417325 Continuation-in-part of Ser. No. US
 1999-248074, filed on 10 Feb 1999, GRANTED, Pat. No. US
 6346512 Continuation-in-part of Ser. No. US
 1997-996679, filed on 23 Dec 1997, GRANTED, Pat. No. US
 6169071 Continuation-in-part of Ser. No. US
 1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US
 6031072 Continuation-in-part of Ser. No. US
 2003-359546, filed on 4 Feb 2003, PENDING Continuation
 of Ser. No. US 1999-248015, filed on 10 Feb 1999,
 GRANTED, Pat. No. US 6562786 Continuation-in-part of
 Ser. No. US 1997-996679, filed on 23 Dec 1997, GRANTED,
 Pat. No. US 6169071 Continuation-in-part of Ser. No. US
 1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US
 6031072

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	61 Drawing Page(s)	
LINE COUNT:	6219	
AB	Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.	

L11 ANSWER 2 OF 29 USPATFULL on STN
 ACCESSION NUMBER: 2004:114177 USPATFULL
 TITLE: Compositions and methods for cell dedifferentiation and
 tissue regeneration
 INVENTOR(S): Keating, Mark T., Chestnut Hill, MA, UNITED STATES
 Odelberg, Shannon J., Salt Lake City, UT, UNITED STATES
 Poss, Kenneth D., Brookline, MA, UNITED STATES
 PATENT ASSIGNEE(S): University of Utah Research Foundation, Salt Lake City,
 UT, UNITED STATES, 84112 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004087016	A1	20040506
APPLICATION INFO.:	US 2002-302812	A1	20021122 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-275828, filed on 4 Apr 2003, PENDING A 371 of International Ser. No. WO 2001-US15582, filed on 14 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-204080P	20000512 (60)
	US 2000-204081P	20000512 (60)
	US 2000-204082P	20000512 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	63	
EXEMPLARY CLAIM:	1	
LINE COUNT:	10731	
AB	The present invention provides methods and compositions to dedifferentiate a cell. The ability of the methods and compositions of	

the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can be used to promote regeneration of tissues and organs in vivo. The ability of the methods and compositions of the present invention to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can further be used to produce populations of stem or progenitor cells which can be used to promote regeneration of tissues and/or organs damaged by injury or disease. Accordingly, the present invention provides novel methods for the treatment of a wide range of injuries and diseases that affect many diverse cell types.

L11 ANSWER 3 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2004:103636 USPATFULL

TITLE: **Implantable drug delivery patch**

INVENTOR(S): Theeuwes, Felix, Los Altos Hills, CA, United States
Nelson, Timothy S., Los Gatos, CA, United States

PATENT ASSIGNEE(S): Durect Corporation, Cupertino, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6726920	B1	20040427
APPLICATION INFO.:	US 2000-668684		20000922 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Azpuru, Carlos A.		
LEGAL REPRESENTATIVE:	Bell, Adam W.		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1400		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features devices and methods for delivery of drug to an internal organ surface by delivery of drug directly to the surface of the organ such that the drug traverses the organ surface and enters the organ tissue. The **device** is in the form of an **implantable drug delivery patch** comprising a first **layer**, which is generally substantially drug-impermeable. When the first **layer** is placed on an outer surface of an organ, a drug reservoir is defined by the first **layer** and the organ surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2004:97377 USPATFULL

TITLE: Compounds and methods for modulating claudin-mediated functions

INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Symonds, James Matthew, Ottawa, CANADA
Gour, Barbara J., Kemptville, CANADA

PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6723700	B1	20040420
APPLICATION INFO.:	US 1999-282029		19990330 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-185908, filed on 3 Nov 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Chan, Christina		

ASSISTANT EXAMINER: Haddad, Maher
LEGAL REPRESENTATIVE: Seed IP Law Group PLLC
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 5699

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain **barrier** permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequence recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:207837 USPATFULL
TITLE: Coadministration of transport protein with conjugated cobalamin to deliver agents
INVENTOR(S): Collins, Douglas A., Rochester, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144198	A1	20030731
APPLICATION INFO.:	US 2002-262318	A1	20020930 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-326183P	20010928 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sherry M. Knowles, King & Spalding, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	3375	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cobalamin transport proteins are administered in combination with cobalamin coupled to a diagnostic or pharmaceutically active agents to increase the extent of absorption of the diagnostic or pharmaceutically active agent. Cobalamin transport proteins include, but are not limited to intrinsic factor, transcobalamin I, transcobalamin II and transcobalamin III. The combination of the cobalamin or cobalamin derivative with the cobalamin transport protein provides enhanced cellular uptake.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:159839 USPATFULL
TITLE: Compounds and methods for modulating adhesion molecule function
INVENTOR(S): Doherty, Patrick, Twickenham, UNITED KINGDOM
Blaschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003109454	A1	20030612
APPLICATION INFO.:	US 2002-193653	A1	20020710 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-351048, filed on 9 Jul 1999, GRANTED, Pat. No. US 6472368 Continuation-in-part of Ser. No. US 1998-113977, filed on 10 Jul 1998, GRANTED, Pat. No. US 6277824		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	62		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3931		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:121162 USPATFULL
 TITLE: Apparatus and methods for variably controlled substance delivery from **implanted** prostheses
 INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
 Yan, John, Los Gatos, CA, UNITED STATES
 PATENT ASSIGNEE(S): AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083646	A1	20030501
APPLICATION INFO.:	US 2001-17500	A1	20011214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	112		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	2731		

AB The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal environments. In particular, the present invention provides luminal prostheses which allow for a programmed and controlled substance delivery protocols for a variety of purposes. The prostheses comprise a scaffold which is **implantable** within a body lumen and a substance reservoir present over at least a portion of the scaffold. Usually, a **rate-controlling** element will be formed over the substance-containing reservoir to provide for a number of different substance release characteristics.

L11 ANSWER 8 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:93775 USPATFULL

TITLE: Compounds and methods for modulating cell adhesion
 INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
 Gour, Barbara J., Kemptville, CANADA
 Farookhi, Riaz, Montreal, CANADA
 Ali, Anmar, Ottawa, CANADA
 PATENT ASSIGNEE(S): McGill University, Montreal, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065136	A1	20030403
APPLICATION INFO.:	US 2002-105008	A1	20020322 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-458870, filed on 10 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-357717, filed on 20 Jul 1999, GRANTED, Pat. No. US 6417325 Continuation-in-part of Ser. No. US 1999-248074, filed on 10 Feb 1999, GRANTED, Pat. No. US 6346512 Continuation-in-part of Ser. No. US 1997-996679, filed on 23 Dec 1997, GRANTED, Pat. No. US 6169071 Continuation-in-part of Ser. No. US 1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US 6031072		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	56 Drawing Page(s)	
LINE COUNT:	5166	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 29 USPATFULL on STN
 ACCESSION NUMBER: 2003:93678 USPATFULL
 TITLE: Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
 INVENTOR(S): Kharazmi, Arsalan, Hellerup, DENMARK
 Christensen, Soren Brogger, Nivaa, DENMARK
 Nielsen, Simon Feldbaek, Herlev, DENMARK
 PATENT ASSIGNEE(S): Statens Serum Institute, Copenhagen K, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065039	A1	20030403
APPLICATION INFO.:	US 2002-62208	A1	20020131 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-462125, filed on 27 Dec 1999, PENDING A 371 of International Ser. No. WO 1998-DK283, filed on 26 Jun 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1997-762	19970626
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,, INTELLECTUAL
PROPERTY PRACTICE GROUP, EDWARDS & ANGELL, LLP., P.O.
BOX 9169, BOSTON, MA, 02209
NUMBER OF CLAIMS: 335
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Page(s)
LINE COUNT: 7715

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:72405 USPATFULL
TITLE: Delivery of therapeutic capable agents
INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S): Avantec Vascular Corporation, Sunnyvale, CA, 94089
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050692	A1	20030313
APPLICATION INFO.:	US 2002-206807	A1	20020725 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-783253, filed on 13 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-782927, filed on 13 Feb 2001, GRANTED, Pat. No. US 6471980 Continuation-in-part of Ser. No. US 2001-783254, filed on 13 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-782804, filed on 13 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2001-17500, filed on 14 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-370703P	20020406 (60)
	US 2002-355317P	20020207 (60)
	US 2002-347473P	20020110 (60)
	US 2001-308381P	20010726 (60)
	US 2000-258024P	20001222 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 2572

AB Devices and methods for reducing, inhibiting, or treating restenosis and hyperplasia after intravascular intervention are provided. In particular, the present invention provides luminal prostheses which allow for controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into a body lumen to reduce smooth muscle cell proliferation.

L11 ANSWER 11 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:38114 USPATFULL

TITLE: Compounds and methods for modulating junctional adhesion molecule-mediated functions

INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Symonds, James Matthew, Ottawa, CANADA
Gour, Barbara J., Kemptville, CANADA

PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027761	A1	20030206
APPLICATION INFO.:	US 2002-119537	A1	20020408 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-324541, filed on 2 Jun 1999, GRANTED, Pat. No. US 6391855		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	2582		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2003:4518 USPATFULL

TITLE: **Drug delivery** platform

INVENTOR(S): Elkins, Christopher J., Redwood City, CA, UNITED STATES
Dake, Michael D., Stanford, CA, UNITED STATES
Waugh, Jacob M., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004564	A1	20030102
APPLICATION INFO.:	US 2002-101455	A1	20020311 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-285383P	20010420 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD,
SUITE 200, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1700

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **stent** based **drug delivery** system. A biological agent of interest is entrapped within a matrix, which is loaded into channels on the surface of a **stent**. The matrix allows for release, usually sustained release, of the entrapped agent. The **stent** and matrix is sheathed with a covalently bound gel. In one embodiment of the invention, the **stent** is used to deliver therapeutic agents to a patient, providing the advantage of efficient delivery and sustained release of an agent at a localized site. In another embodiment of the invention, the **drug delivery** system is used for testing and comparison of candidate drugs in an in vivo setting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 29 USPATFULL on STN
ACCESSION NUMBER: 2002:337929 USPATFULL
TITLE: COMPOUNDS AND METHODS FOR MODULATING CLAUDIN-MEDIATED FUNCTIONS
INVENTOR(S): BLASCHUK, OREST W., WESTMOUNT, CANADA
SYMONDS, JAMES MATTHEW, OTTAWA, CANADA
GOUR, BARBARA J., KEMPTVILLE, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193294	A1	20021219
APPLICATION INFO.:	US 1998-185908	A1	19981103 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	63		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	4384		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain **barrier** permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 29 USPATFULL on STN
ACCESSION NUMBER: 2002:283259 USPATFULL
TITLE: Compounds and methods for modulating adhesion molecule function
INVENTOR(S): Doherty, Patrick, Twickenham, UNITED KINGDOM
Blaschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6472368	B1	20021029
APPLICATION INFO.:	US 1999-351048		19990709 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-113977, filed on 10 Jul 1998, now patented, Pat. No. US 6277824		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Chan, Christina Y.		
ASSISTANT EXAMINER:	Haddad, Maher		
LEGAL REPRESENTATIVE:	SEED Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	3743		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:273397 USPATFULL

TITLE: Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation

INVENTOR(S): Collins, Douglas A., Rochester, MN, UNITED STATES
Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151525	A1	20021017
APPLICATION INFO.:	US 2001-27593	A1	20011025 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-243082P	20001025 (60)
	US 2000-243112P	20001025 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	4143	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An agent, composition and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:273347 USPATFULL

TITLE: Compounds and methods for modulating cell adhesion

INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Kemptville, CANADA

PATENT ASSIGNEE(S): McGill University, Montreal, CANADA, K1G 5Z3 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151475	A1	20021017
APPLICATION INFO.:	US 2001-6982	A1	20011204 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507102, filed on 17 Feb 2000, GRANTED, Pat. No. US 6326352 Continuation of Ser. No. US 1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US 6031072		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	82	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	2807	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:268732 USPATFULL

TITLE: Compounds and methods for modulating cell adhesion

INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Kemptville, CANADA
Farookhi, Riaz, Montreal, CANADA
Ali, Anmar, Ottawa, CANADA

PATENT ASSIGNEE(S): McGill University, Montreal, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6465427	B1	20021015
APPLICATION INFO.:	US 1999-458870		19991210 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-357717, filed on 20 Jul 1999 Continuation-in-part of Ser. No. US 1999-248074, filed on 10 Feb 1999, now patented, Pat. No. US 6346512 Continuation-in-part of Ser. No. US 1997-996679, filed on 23 Dec 1997, now patented, Pat. No. US 6169071 Continuation-in-part of Ser. No. US 1997-893534, filed on 11 Jul 1997, now patented, Pat. No. US 6031072		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davenport, Avis M.	
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	101 Drawing Figure(s); 56 Drawing Page(s)	

LINE COUNT: 5017

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:158065 USPATFULL

TITLE: Delivery or therapeutic capable agents

INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES

Yan, John, Los Gatos, CA, UNITED STATES

PATENT ASSIGNEE(S): AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002082679	A1	20020627
APPLICATION INFO.:	US 2001-2595	A1	20011101 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-258024P	20001222 (60)
	US 2001-308381P	20010726 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	271	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	3153	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **device** and a method using the same, for reducing restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for controlled release of at least one therapeutic capable agent with increased efficacy to selected locations within a patient's vasculature to reduce restenosis. An intraluminal prosthesis may comprise an expandable structure and a source adjacent the expandable structure for releasing the therapeutic capable agent into the body lumen to reduce smooth muscle cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:116254 USPATFULL

TITLE: Compounds and methods for modulating junctional adhesion molecule-mediated functions

INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA

Symonds, James Matthew, Ottawa, CANADA

Gour, Barbara J., Kemptville, CANADA

PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391855	B1	20020521
APPLICATION INFO.:	US 1999-324541		19990602 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Saunders, David		
ASSISTANT EXAMINER:	DeCloux, Amy		

LEGAL REPRESENTATIVE: SEED Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:92631 USPATFULL
TITLE: Cobalamin compounds useful as cardiovascular agents and as imaging agents
INVENTOR(S): Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049155	A1	20020425
APPLICATION INFO.:	US 2001-873142	A1	20010531 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208140P	20000531 (60)
	US 2001-267782P	20010209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	4521	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cobalamin derivatives linked to a cardiovascular agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2002:78737 USPATFULL
TITLE: Cobalamin compounds useful as antibiotic agents and as imaging agents
INVENTOR(S): Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
Collins, Douglas A., Rochester, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042394	A1	20020411
APPLICATION INFO.:	US 2001-873164	A1	20010531 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208148P	20000531 (60)
	US 2001-267543P	20010209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA,
GA, 30303-1763
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 4896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cobalamin derivatives linked to an antibiotic and/or an imaging agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a microbial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 29 USPATFULL on STN
ACCESSION NUMBER: 2002:29367 USPATFULL
TITLE: Compounds and methods for modulating cell adhesion
INVENTOR(S): Blaschuk, Orest W., Westmount, CANADA
Gour, Barbara J., Montreal, CANADA
PATENT ASSIGNEE(S): McGill University, Montreal, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6346512	B1	20020212
APPLICATION INFO.:	US 1999-248074		19990210 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-996679, filed on 23 Dec 1997 Continuation-in-part of Ser. No. US 1997-893534, filed on 11 Jul 1997, now patented, Pat. No. US 6031072		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Moezie, F. T.	
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	59 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	4110	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 29 USPATFULL on STN
ACCESSION NUMBER: 2001:221030 USPATFULL
TITLE: Compounds and methods for modulating cell adhesion
INVENTOR(S): Blaschuk, Orest W., Westmount, Canada
Gour, Barbara J., Beaconsfield, Canada
PATENT ASSIGNEE(S): McGill University, Montreal, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326352	B1	20011204
APPLICATION INFO.:	US 2000-507102		20000217 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-893534, filed on 11 Jul 1997, now patented, Pat. No. US 6031072

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davenport, Avis M.	
LEGAL REPRESENTATIVE:	SEED Intellectual Property Law Group PLLC	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	45 Drawing Figure(s); 24 Drawing Page(s)	
LINE COUNT:	2466	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2001:191243 USPATFULL
TITLE: Compounds and methods for modulating tissue permeability
INVENTOR(S): Blaschuk, Orest W., Westmount, Canada
Symonds, James Matthew, Ottawa, Canada
Gour, Barbara J., Kemptville, Canada
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6310177	B1	20011030
APPLICATION INFO.:	US 2000-510616		20000222 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-1511, filed on 31 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2343		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2001:136627 USPATFULL
TITLE: Compounds and methods for modulating adhesion molecule function

INVENTOR(S): Doherty, Patrick, Twickenham, United Kingdom
Blaschuk, Orest W., Westmount, Canada
Gour, Barbara J., Montreal, Canada
PATENT ASSIGNEE(S): Adherex Technologies, Ottawa, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277824	B1	20010821
APPLICATION INFO.:	US 1998-113977		19980710 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Chan, Christina Y.		
ASSISTANT EXAMINER:	DiBrino, Marianne		
LEGAL REPRESENTATIVE:	Seed IP Law Group PLLC		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3160		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2001:93630 USPATFULL
TITLE: Compounds and methods and modulating tissue permeability
INVENTOR(S): Blaschuk, Orest W., Westmount, Canada
Symonds, James Matthew, Ottawa, Canada
Gour, Barbara J., Beaconsfield, Canada
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Ontario, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248864	B1	20010619
APPLICATION INFO.:	US 1997-1511		19971231 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2277		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2001:1758 USPATFULL
TITLE: Compounds and methods for modulating cell adhesion
INVENTOR(S): Blaschuk, Orest W., Westmount, Canada
Gour, Barbara J., Montreal, Canada
PATENT ASSIGNEE(S): McGill University, Montreal, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6169071	B1	20010102
APPLICATION INFO.:	US 1997-996679		19971223 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-893534, filed on 11 Jul 1997, now patented, Pat. No. US 6031072		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Moezie, F. T.	
LEGAL REPRESENTATIVE:	Seed IP Law Group	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	55 Drawing Figure(s); 34 Drawing Page(s)	
LINE COUNT:	3369	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2000:113775 USPATFULL
TITLE: Compounds and methods for modulating tissue permeability
INVENTOR(S): Blaschuk, Orest W., Westmount, Canada
Symonds, James Matthew, Ottawa, Canada
Gour, Barbara J., Kemptville, Canada
PATENT ASSIGNEE(S): Adherex Technologies Inc., Ottawa, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6110747		20000829
APPLICATION INFO.:	US 1998-222373		19981229 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-1511, filed on 31 Dec 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Seed IP Law Group PLLC		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2887		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents

may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 29 USPATFULL on STN

ACCESSION NUMBER: 2000:24746 USPATFULL
TITLE: Compounds and methods for modulating cell adhesion
INVENTOR(S): Blaschuk, Orest W., Westmount, Canada
Gour, Barbara J., Beaconsfield, Canada
PATENT ASSIGNEE(S): McGill University, Montreal, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6031072		20000229
APPLICATION INFO.:	US 1997-893534		19970711 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-21612P	19960712 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Davenport, Avis M.	
LEGAL REPRESENTATIVE:	Seed and Berry LLP	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 24 Drawing Page(s)	
LINE COUNT:	2900	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file uspatful		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	128.54	128.75

FILE 'USPATFULL' ENTERED AT 16:32:08 ON 17 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 17 Jun 2004 (20040617/PD)
FILE LAST UPDATED: 17 Jun 2004 (20040617/ED)
HIGHEST GRANTED PATENT NUMBER: US6751803
HIGHEST APPLICATION PUBLICATION NUMBER: US2004117887
CA INDEXING IS CURRENT THROUGH 17 Jun 2004 (20040617/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 17 Jun 2004 (20040617/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>> USPAT2 is now available. USPATFULL contains full text of the	<<<
>>> original, i.e., the earliest published granted patents or	<<<
>>> applications. USPAT2 contains full text of the latest US	<<<
>>> publications, starting in 2001, for the inventions covered in	<<<

```

>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

```

```

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```

=> s (drug delivery) and implant?
    140629 DRUG
    293102 DELIVERY
    26472 DRUG DELIVERY
        (DRUG(W) DELIVERY)
    148676 IMPLANT?
L12    13094 (DRUG DELIVERY) AND IMPLANT?

```

```

=> s l12 and (sheath or barrier)
    69943 SHEATH
    202255 BARRIER
L13    5161 L12 AND (SHEATH OR BARRIER)

```

```

=> s l13 and caot?
    235 CAOT?
L14    2 L13 AND CAOT?

```

```

=> s l13 and coat?
    773478 COAT?
L15    4388 L13 AND COAT?

```

```

=> s l15 and substrate
    565560 SUBSTRATE
L16    2861 L15 AND SUBSTRATE

```

```

=> s l16 and partial?
    1317617 PARTIAL?
L17    2458 L16 AND PARTIAL?

```

```

=> s l17 and biodegradable
    32585 BIODEGRADABLE
L18    1412 L17 AND BIODEGRADABLE

```

```

=> s l18 and (rate control?)
    1150304 RATE
    2263764 CONTROL?
    23000 RATE CONTROL?
        (RATE(W) CONTROL?)
L19    51 L18 AND (RATE CONTROL?)

```

```

=> s l19 an polymer?
MISSING OPERATOR L19 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

```

```

=> .

```

. IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L19 and polymer?

619461 POLYMER?

L20 51 L19 AND POLYMER?

=> s L20 and multilayer?

73163 MULTILAYER?

L21 0 L20 AND MULTILAYER?

=> s L20 and (stent or catheter)

9763 STENT

46168 CATHETER

L22 21 L20 AND (STENT OR CATHETER)

=> d l22 1-21

L22 ANSWER 1 OF 21 USPATFULL on STN

AN 2004:139369 USPATFULL

TI Compounds and methods for modulating cell adhesion

IN Blaschuk, Orest W., Westmount, CANADA

Gour, Barbara J., Kemptville, CANADA

Farookhi, Riaz, Montreal, CANADA

Ali, Anmar, San Diego, CA, UNITED STATES

PI US 2004106545 A1 20040603

AI US 2003-632678 A1 20030801 (10)

RLI Continuation-in-part of Ser. No. US 2003-464071, filed on 18 Jun 2003,
PENDING Continuation of Ser. No. US 2000-544782, filed on 7 Apr 2000,
GRANTED, Pat. No. US 6610821 Continuation-in-part of Ser. No. US
1999-458870, filed on 10 Dec 1999, GRANTED, Pat. No. US 6465427
Continuation-in-part of Ser. No. US 1999-357717, filed on 20 Jul 1999,
GRANTED, Pat. No. US 6417325 Continuation-in-part of Ser. No. US
1999-248074, filed on 10 Feb 1999, GRANTED, Pat. No. US 6346512
Continuation-in-part of Ser. No. US 1997-996679, filed on 23 Dec 1997,
GRANTED, Pat. No. US 6169071 Continuation-in-part of Ser. No. US
1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US 6031072
Continuation-in-part of Ser. No. US 2003-359546, filed on 4 Feb 2003,
PENDING Continuation of Ser. No. US 1999-248015, filed on 10 Feb 1999,
GRANTED, Pat. No. US 6562786 Continuation-in-part of Ser. No. US
1997-996679, filed on 23 Dec 1997, GRANTED, Pat. No. US 6169071
Continuation-in-part of Ser. No. US 1997-893534, filed on 11 Jul 1997,
GRANTED, Pat. No. US 6031072

PRAI US 1996-21612P 19960712 (60)

US 1996-21612P 19960712 (60)

DT Utility

FS APPLICATION

LN.CNT 6219

INCL INCLM: 514/009.000

INCLS: 530/317.000

NCL NCLM: 514/009.000

NCLS: 530/317.000

IC [7]

ICM: A61K038-12

ICS: C07K005-12; C07K007-64

L22 ANSWER 2 OF 21 USPATFULL on STN

AN 2004:114177 USPATFULL

TI Compositions and methods for cell dedifferentiation and tissue
regeneration

IN Keating, Mark T., Chestnut Hill, MA, UNITED STATES

Odelberg, Shannon J., Salt Lake City, UT, UNITED STATES

Poss, Kenneth D., Brookline, MA, UNITED STATES

PA University of Utah Research Foundation, Salt Lake City, UT, UNITED STATES, 84112 (U.S. corporation)
PI US 2004087016 A1 20040506
AI US 2002-302812 A1 20021122 (10)
RLI Continuation-in-part of Ser. No. US 2003-275828, filed on 4 Apr 2003, PENDING A 371 of International Ser. No. WO 2001-US15582, filed on 14 May 2001, PENDING
PRAI US 2000-204080P 20000512 (60)
US 2000-204081P 20000512 (60)
US 2000-204082P 20000512 (60)
DT Utility
FS APPLICATION
LN.CNT 10731
INCL INCLM: 435/366.000
INCLS: 424/093.700
NCL NCLM: 435/366.000
NCLS: 424/093.700
IC [7]
ICM: C12N005-08
ICS: A61K045-00

L22 ANSWER 3 OF 21 USPATFULL on STN
AN 2004:108237 USPATFULL
TI N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
IN Ho, Chih Yung, Lansdale, PA, UNITED STATES
Brunmark, Bengt Anders, LaJolla, CA, UNITED STATES
Emanuel, Stuart, Doylestown, PA, UNITED STATES
Galemmo, Robert A., JR., Collegeville, PA, UNITED STATES
Johnson, Dana L., Upper Black Eddy, PA, UNITED STATES
Ludovici, Donald W., Quakertown, PA, UNITED STATES
Maharroof, Umar, North Wales, PA, UNITED STATES
Mei, Jay M., North Wales, PA, UNITED STATES
Sechler, Jan L., Doylestown, PA, UNITED STATES
Strobel, Eric D., Hatboro, PA, UNITED STATES
Tuman, Robert W., Chalfont, PA, UNITED STATES
Yen, Hwa Kwo, Malvern, PA, UNITED STATES
PI US 2004082639 A1 20040429
AI US 2003-438152 A1 20030514 (10)
PRAI US 2002-380735P 20020515 (60)
DT Utility
FS APPLICATION
LN.CNT 13168
INCL INCLM: 514/405.000
INCLS: 548/359.100; 548/360.100
NCL NCLM: 514/405.000
NCLS: 548/359.100; 548/360.100
IC [7]
ICM: A61K031-415
ICS: C07D231-56; C07D231-54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 21 USPATFULL on STN
AN 2004:103636 USPATFULL
TI **Implantable drug delivery patch**
IN Theeuwes, Felix, Los Altos Hills, CA, United States
Nelson, Timothy S., Los Gatos, CA, United States
PA Durect Corporation, Cupertino, CA, United States (U.S. corporation)
PI US 6726920 B1 20040427
AI US 2000-668684 20000922 (9)
DT Utility
FS GRANTED
LN.CNT 1400
INCL INCLM: 424/423.000
INCLS: 424/422.000; 424/424.000; 424/425.000; 424/426.000; 424/447.000;

424/448.000; 424/449.000; 604/019.000
NCL NCLM: 424/423.000
NCLS: 424/422.000; 424/424.000; 424/425.000; 424/426.000; 424/447.000;
424/448.000; 424/449.000; 604/019.000

IC [7]
ICM: A61F002-02
ICS: A61F013-02; A61L015-16; A61K009-70; A61N001-30
EXF 424/422; 424/423; 424/424; 424/425; 424/426; 424/447; 424/448; 424/449;
604/19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 21 USPATFULL on STN
AN 2004:95568 USPATFULL
TI Phosphorus-containing compounds and uses thereof
IN Metcalf, Chester A., III, Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Bernstein, David L., Waban, MA, UNITED STATES
PI US 2004073024 A1 20040415
AI US 2003-635054 A1 20030806 (10)
RLI Continuation-in-part of Ser. No. US 2003-357152, filed on 3 Feb 2003,
PENDING
PRAI US 2002-353252P 20020201 (60)
US 2002-426928P 20021115 (60)
US 2002-428383P 20021122 (60)
US 2002-433930P 20021217 (60)

DT Utility
FS APPLICATION
LN.CNT 3658
INCL INCLM: 540/456.000
NCL NCLM: 540/456.000
IC [7]
ICM: C07D498-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 21 USPATFULL on STN
AN 2004:30716 USPATFULL
TI **Polymer-based, sustained release drug
delivery system**
IN Ashton, Paul, Boston, MA, UNITED STATES
Chen, Jianbing, Belmont, MA, UNITED STATES
Guo, Hong, Belmont, MA, UNITED STATES
PA Control Delivery Systems, Inc., Watertown, MA, UNITED STATES (U.S.
corporation)
PI US 2004022853 A1 20040205
AI US 2003-449855 A1 20030530 (10)
RLI Continuation-in-part of Ser. No. US 2002-134033, filed on 26 Apr 2002,
PENDING Continuation-in-part of Ser. No. WO 2002-US13385, filed on 26
Apr 2002, PENDING
PRAI US 2001-286343P 20010426 (60)
US 2001-322428P 20010917 (60)
US 2002-372761P 20020415 (60)

DT Utility
FS APPLICATION
LN.CNT 1789
INCL INCLM: 424/468.000
NCL NCLM: 424/468.000
IC [7]
ICM: A61K009-22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 7 OF 21 USPATFULL on STN
AN 2003:312692 USPATFULL
TI Phosphorus-containing compounds and uses thereof
IN Bernstein, David L., Waban, MA, UNITED STATES

Metcalfe, Chester A., III, Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES

PI US 2003220297 A1 20031127
AI US 2003-357152 A1 20030203 (10)
PRAI US 2002-353252P 20020201 (60)
US 2002-426928P 20021115 (60)
US 2002-428383P 20021122 (60)
US 2002-433930P 20021217 (60)

DT Utility
FS APPLICATION
LN.CNT 3696

INCL INCLM: 514/080.000
INCLS: 540/456.000
NCL NCLM: 514/080.000
NCLS: 540/456.000

IC [7]
ICM: A61K031-675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 8 OF 21 USPATFULL on STN

AN 2003:207837 USPATFULL

TI Coadministration of transport protein with conjugated cobalamin to deliver agents

IN Collins, Douglas A., Rochester, MN, UNITED STATES

PI US 2003144198 A1 20030731
AI US 2002-262318 A1 20020930 (10)
PRAI US 2001-326183P 20010928 (60)

DT Utility
FS APPLICATION
LN.CNT 3375

INCL INCLM: 514/012.000
INCLS: 514/052.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 514/052.000; 530/350.000

IC [7]
ICM: A61K038-17
ICS: A61K031-714; C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 9 OF 21 USPATFULL on STN

AN 2003:121162 USPATFULL

TI Apparatus and methods for variably controlled substance delivery from implanted prostheses

IN Sirhan, Motasim, Sunnyvale, CA, UNITED STATES

Yan, John, Los Gatos, CA, UNITED STATES

PA AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)

PI US 2003083646 A1 20030501
AI US 2001-17500 A1 20011214 (10)

RLI Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001, PENDING

DT Utility
FS APPLICATION
LN.CNT 2731

INCL INCLM: 604/891.100
INCLS: 623/001.150; 623/001.420
NCL NCLM: 604/891.100
NCLS: 623/001.150; 623/001.420

IC [7]
ICM: A61F002-06

L22 ANSWER 10 OF 21 USPATFULL on STN

AN 2003:101978 USPATFULL

TI Drug delivery catheters that attach to tissue and methods for their use

IN Altman, Peter A., South San Francisco, CA, United States
Hakem, Brian, South San Francisco, CA, United States
PA BioCardia, Inc., San Francisco, CA, United States (U.S. corporation)
PI US 6547787 B1 20030415
AI US 1999-418206 19991013 (9)
RLI Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997
DT Utility
FS GRANTED
LN.CNT 2046

INCL INCLM: 606/041.000
INCLS: 607/003.000; 607/120.000
NCL NCLM: 606/041.000
NCLS: 607/003.000; 607/120.000

IC [7]
ICM: A61N001-05
EXF 606/41; 606/47; 606/85; 606/48; 606/44; 600/374; 600/508; 600/424;
607/3; 607/120-122; 607/126-128; 607/60-61; 607/32-33

L22 ANSWER 11 OF 21 USPATFULL on STN

AN 2003:72405 USPATFULL
TI Delivery of therapeutic capable agents
IN Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
Yan, John, Los Gatos, CA, UNITED STATES
PA Avantec Vascular Corporation, Sunnyvale, CA, 94089 (U.S. corporation)
PI US 2003050692 A1 20030313
AI US 2002-206807 A1 20020725 (10)
RLI Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001,
PENDING Continuation-in-part of Ser. No. US 2001-783253, filed on 13 Feb
2001, PENDING Continuation-in-part of Ser. No. US 2001-782927, filed on
13 Feb 2001, GRANTED, Pat. No. US 6471980 Continuation-in-part of Ser.
No. US 2001-783254, filed on 13 Feb 2001, PENDING Continuation-in-part
of Ser. No. US 2001-782804, filed on 13 Feb 2001, PENDING
Continuation-in-part of Ser. No. US 2001-17500, filed on 14 Dec 2001,
PENDING

PRAI US 2002-370703P 20020406 (60)
US 2002-355317P 20020207 (60)
US 2002-347473P 20020110 (60)
US 2001-308381P 20010726 (60)
US 2000-258024P 20001222 (60)

DT Utility
FS APPLICATION
LN.CNT 2572

INCL INCLM: 623/001.420
INCLS: 623/001.430
NCL NCLM: 623/001.420
NCLS: 623/001.430

IC [7]
ICM: A61F002-06

L22 ANSWER 12 OF 21 USPATFULL on STN

AN 2003:4518 USPATFULL
TI **Drug delivery** platform
IN Elkins, Christopher J., Redwood City, CA, UNITED STATES
Dake, Michael D., Stanford, CA, UNITED STATES
Waugh, Jacob M., Palo Alto, CA, UNITED STATES

PI US 2003004564 A1 20030102
AI US 2002-101455 A1 20020311 (10)
PRAI US 2001-285383P 20010420 (60)

DT Utility
FS APPLICATION
LN.CNT 1700

INCL INCLM: 623/001.150
NCL NCLM: 623/001.150
IC [7]

ICM: A61F002-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 13 OF 21 USPATFULL on STN
AN 2002:315281 USPATFULL
TI **Drug delivery** catheters that attach to tissue and
methods for their use
IN Altman, Peter A., South San Francisco, CA, UNITED STATES
Altman, John D., South San Francisco, CA, UNITED STATES
Stertz, Simon, South San Francisco, CA, UNITED STATES
PI US 2002177772 A1 20021128
AI US 2002-190429 A1 20020705 (10)
RLI Continuation of Ser. No. US 1999-418205, filed on 13 Oct 1999, GRANTED,
Pat. No. US 6416510 Continuation-in-part of Ser. No. US 1997-816850,
filed on 13 Mar 1997, GRANTED, Pat. No. US 6086582
DT Utility
FS APPLICATION
LN.CNT 2055
INCL INCLM: 600/431.000
INCLS: 607/120.000
NCL NCLM: 600/431.000
NCLS: 607/120.000
IC [7]
ICM: A61N001-00

L22 ANSWER 14 OF 21 USPATFULL on STN
AN 2002:273397 USPATFULL
TI Transcobalamin receptor binding conjugates useful for treating abnormal
cellular proliferation
IN Collins, Douglas A., Rochester, MN, UNITED STATES
Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
PI US 2002151525 A1 20021017
AI US 2001-27593 A1 20011025 (10)
PRAI US 2000-243082P 20001025 (60)
US 2000-243112P 20001025 (60)
DT Utility
FS APPLICATION
LN.CNT 4143
INCL INCLM: 514/080.000
INCLS: 540/145.000
NCL NCLM: 514/080.000
NCLS: 540/145.000
IC [7]
ICM: A61K031-675
ICS: C07F015-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 15 OF 21 USPATFULL on STN
AN 2002:198316 USPATFULL
TI **Drug delivery** devices comprising
biodegradable protein for the controlled release of
pharmacologically active agents and method of making the **drug**
delivery devices
IN Masters, David B., Hastings, MN, UNITED STATES
PA Gel-Del Technologies, Inc. (U.S. corporation)
PI US 2002106410 A1 20020808
AI US 2001-14947 A1 20011211 (10)
RLI Continuation of Ser. No. US 1998-160421, filed on 25 Sep 1998, PATENTED
PRAI US 1997-60048P 19970925 (60)
DT Utility
FS APPLICATION
LN.CNT 1828
INCL INCLM: 424/484.000
INCLS: 514/002.000
NCL NCLM: 424/484.000
NCLS: 514/002.000

IC [7]
ICM: A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 16 OF 21 USPATFULL on STN
AN 2002:167670 USPATFULL
TI **Drug delivery** catheters that attach to tissue and
methods for their use
IN Altman, Peter A., South San Francisco, CA, United States
Altman, John D., South San Francisco, CA, United States
Stertz, Simon, South San Francisco, CA, United States
PA Biocardia, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6416510 B1 20020709
AI US 1999-418205 19991013 (9)
RLI Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997
DT Utility
FS GRANTED
LN.CNT 2112
INCL INCLM: 606/041.000
INCLS: 607/120.000; 607/003.000
NCL NCLM: 606/041.000
NCLS: 607/003.000; 607/120.000
IC [7]
ICM: A61N001-05
EXF 607/120; 607/121; 607/122; 607/123; 607/3; 607/126; 607/127; 607/128;
607/60-61; 607/32-33; 606/41; 606/45; 606/47; 606/48; 606/44; 606/167;
600/508; 600/374; 604/22; 604/264; 604/95; 604/200; 604/73; 604/181;
604/187; 604/131; 604/141; 604/143; 604/148; 604/280

L22 ANSWER 17 OF 21 USPATFULL on STN
AN 2002:158065 USPATFULL
TI Delivery or therapeutic capable agents
IN Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
Yan, John, Los Gatos, CA, UNITED STATES
PA AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)
PI US 2002082679 A1 20020627
AI US 2001-2595 A1 20011101 (10)
PRAI US 2000-258024P 20001222 (60)
US 2001-308381P 20010726 (60)
DT Utility
FS APPLICATION
LN.CNT 3153
INCL INCLM: 623/001.150
INCLS: 623/001.420; 424/426.000
NCL NCLM: 623/001.150
NCLS: 623/001.420; 424/426.000
IC [7]
ICM: A61F002-06
ICS: A61F002-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 18 OF 21 USPATFULL on STN
AN 2002:92631 USPATFULL
TI Cobalamin compounds useful as cardiovascular agents and as imaging
agents
IN Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
PI US 2002049155 A1 20020425
AI US 2001-873142 A1 20010531 (9)
PRAI US 2000-208140P 20000531 (60)
US 2001-267782P 20010209 (60)
DT Utility
FS APPLICATION
LN.CNT 4521
INCL INCLM: 514/007.000

NCL NCLM: 514/007.000

IC [7]

ICM: A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 19 OF 21 USPATFULL on STN

AN 2002:78737 USPATFULL

TI Cobalamin compounds useful as antibiotic agents and as imaging agents

IN Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

Collins, Douglas A., Rochester, MN, UNITED STATES

PI US 2002042394 A1 20020411

AI US 2001-873164 A1 20010531 (9)

PRAI US 2000-208148P 20000531 (60)

US 2001-267543P 20010209 (60)

DT Utility

FS APPLICATION

LN.CNT 4896

INCL INCLM: 514/053.000

INCLS: 514/185.000; 540/145.000; 536/026.440

NCL NCLM: 514/053.000

NCLS: 514/185.000; 540/145.000; 536/026.440

IC [7]

ICM: A61K031-714

ICS: A61K031-555; C07H023-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 20 OF 21 USPATFULL on STN

AN 2002:48052 USPATFULL

TI Protein matrix materials, devices and methods of making and using thereof

IN Masters, David B., Hastings, MN, UNITED STATES

PI US 2002028243 A1 20020307

AI US 2001-796170 A1 20010228 (9)

RLI Continuation-in-part of Ser. No. US 1998-160421, filed on 25 Sep 1998, ABANDONED

PRAI US 2000-185420P 20000228 (60)

US 2000-222762P 20000803 (60)

DT Utility

FS APPLICATION

LN.CNT 3903

INCL INCLM: 424/484.000

NCL NCLM: 424/484.000

IC [7]

ICM: A61K009-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 21 OF 21 USPATFULL on STN

AN 2002:19086 USPATFULL

TI **Drug delivery** devices comprising **biodegradable** protein for the controlled release of pharmacologically active agents and method of making the **drug delivery** devices

IN Masters, David B., Hastings, MN, United States

PA Gel-Del Technologies, Inc., Saint Paul, MN, United States (U.S. corporation)

PI US 6342250 B1 20020129

AI US 1998-160421 19980925 (9)

PRAI US 1997-60048P 19970925 (60)

DT Utility

FS GRANTED

LN.CNT 1740

INCL INCLM: 424/484.000

INCLS: 424/468.000; 424/443.000

NCL NCLM: 424/484.000

NCLS: 424/443.000; 424/468.000

IC [7]
ICM: A61K009-10
ICS: A61K009-22; A61K009-70; A61K047-42
EXF 424/486; 424/484; 424/464-465; 424/468; 424/489; 424/400; 424/443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L22 6 9 15 21 ibib abs

L22 ANSWER 6 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2004:30716 USPATFULL
TITLE: **Polymer-based, sustained release drug delivery system**
INVENTOR(S): Ashton, Paul, Boston, MA, UNITED STATES
Chen, Jianbing, Belmont, MA, UNITED STATES
Guo, Hong, Belmont, MA, UNITED STATES
PATENT ASSIGNEE(S): Control Delivery Systems, Inc., Watertown, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004022853	A1	20040205
APPLICATION INFO.:	US 2003-449855	A1	20030530 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-134033, filed on 26 Apr 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US13385, filed on 26 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-286343P	20010426 (60)
	US 2001-322428P	20010917 (60)
	US 2002-372761P	20020415 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1789	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a sustained release system that includes a **polymer** and a pharmaceutically active agent dispersed in the **polymer**. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the granules into the **polymer** matrix. Advantageously, the **polymer** is permeable to the agent and is non-release-rate-with limiting with respect to the rate of release of the agent from the **polymer**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 9 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2003:121162 USPATFULL
TITLE: Apparatus and methods for variably controlled substance delivery from **implanted** prostheses
INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S): AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003083646	A1	20030501
APPLICATION INFO.:	US 2001-17500	A1	20011214 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-2595, filed on
1 Nov 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 112
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Page(s)
LINE COUNT: 2731

AB The present invention provides improved stents and other prostheses for
delivering substances to vascular and other luminal and intracorporeal
environments. In particular, the present invention provides luminal
prostheses which allow for a programmed and controlled substance
delivery protocols for a variety of purposes. The prostheses comprise a
scaffold which is **implantable** within a body lumen and a
substance reservoir present over at least a portion of the scaffold.
Usually, a **rate-controlling** element will be formed
over the substance-containing reservoir to provide for a number of
different substance release characteristics.

L22 ANSWER 15 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2002:198316 USPATFULL

TITLE: **Drug delivery** devices comprising
biodegradable protein for the controlled
release of pharmacologically active agents and method
of making the **drug delivery** devices
INVENTOR(S): Masters, David B., Hastings, MN, UNITED STATES
PATENT ASSIGNEE(S): Gel-Del Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106410	A1	20020808
APPLICATION INFO.:	US 2001-14947	A1	20011211 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-160421, filed on 25 Sep 1998, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60048P	19970925 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	John F. Dolan, Fredrikson & Byron, P.A., 1100 International Centre, 900 Second Avenue South, Minneapolis, MN, 55408-3397	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1828	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method of making
drug delivery devices for the controlled release of
pharmacologically active agents and further, to **drug**
delivery devices made by such method. More specifically, the
present invention relates to a method of forming a film comprising one
or more **biodegradable polymeric** materials, one or
more pharmacologically active agents, and one or more biocompatible
solvents. The film is then **partially** dried, rolled or
otherwise shaped, and then compressed. In this manner, the amount of
pharmacologically active agent(s) that can be incorporated into the
drug delivery device is increased and the
pharmacologically active agent(s) is/are substantially homogeneously
distributed throughout the **drug delivery** device. As
a result, the release characteristics of the pharmacologically active

agent from the **drug delivery** device are enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 21 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2002:19086 USPATFULL

TITLE: **Drug delivery** devices comprising
biodegradable protein for the controlled
release of pharmacologically active agents and method
of making the **drug delivery** devices

INVENTOR(S): Masters, David B., Hastings, MN, United States

PATENT ASSIGNEE(S): Gel-Del Technologies, Inc., Saint Paul, MN, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342250	B1	20020129
APPLICATION INFO.:	US 1998-160421		19980925 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60048P	19970925 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Webman, Edward J.	
LEGAL REPRESENTATIVE:	Fredrikson & Byron, PA	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1740	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method of making
drug delivery devices for the controlled release of
pharmacologically active agents and further, to **drug**
delivery devices made by such method. More specifically, the
present invention relates to a method of forming a film comprising one
or more **biodegradable polymeric** materials, one or
more pharmacologically active agents, and one or more biocompatible
solvents. The film is then **partially** dried, rolled or
otherwise shaped, and then compressed. In this manner, the amount of
pharmacologically active agent(s) that can be incorporated into the
drug delivery device is increased and the
pharmacologically active agent(s) is/are substantially homogeneously
distributed throughout the **drug delivery** device. As
a result, the release characteristics of the pharmacologically active
agent from the **drug delivery** device are enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus uspatful europatful japio medline biosis embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.68	182.43

FILE 'CAPLUS' ENTERED AT 16:44:07 ON 17 JUN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:44:07 ON 17 JUN 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:44:07 ON 17 JUN 2004

COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:44:07 ON 17 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:44:07 ON 17 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:44:07 ON 17 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:44:07 ON 17 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s implant? and (drug delivery)

2 FILES SEARCHED...

L23 24191 IMPLANT? AND (DRUG DELIVERY)

=> s L23 and (partial coat?)

L24 19 L23 AND (PARTIAL COAT?)

=> d l24 1-19 ibib abs

L24 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:585364 CAPLUS

DOCUMENT NUMBER: 129:207202

TITLE: **Implant** compositions containing a
biologically active protein, peptide or polypeptide
INVENTOR(S): Steber, William David; Cady, Susan Mancini; Johnson,
David Farley; Haughey, Theresa Rice

PATENT ASSIGNEE(S): American Cyanamid Co., USA

SOURCE: U.S., 14 pp., Cont.-in-part of U. S. 97,548,
abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5801141	A	19980901	US 1995-456167	19950531
PRIORITY APPLN. INFO.:			US 1991-719898	B2 19910624
			US 1993-97548	B2 19930726

AB The invention relates to **implants** for the parenteral
administration of an essentially uniform and continuous amount of a biol.
active protein, peptide or polypeptide over an extended period of time
which comprises a compacted, indented and partially coated composition
containing

from one to three layers of a homogeneous core mixture comprising about 20%
to about 80% of a biol. active protein, a peptide or a polypeptide; about
10% to about 75% of a fat, a wax or a mixture thereof; 0% to about 25% of a
buffer, a salt, a sugar or a mixture thereof; 0% to about 15% of a filler,
on a weight basis of the total weight of the core mixture The **partial
coating** of a semipermeable material comprises about 5% to about
50%, on a weight basis of the total weight of the **implant**. The
invention also relates to methods for increasing and maintaining elevated
blood levels of biol. active proteins, peptides and polypeptides in
animals by the administration of said **implants**.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2004:117838 USPATFULL

TITLE: Mechanical and acoustical suspension coating of medical
implants

INVENTOR(S): Schwarz, Marlene C., Auburndale, MA, UNITED STATES

Tocker, Stanley, Wilmington, DE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004089230	A1	20040513
APPLICATION INFO.:	US 2003-699771	A1	20031104 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-84868, filed on 1 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-804040, filed on 13 Mar 2001, GRANTED, Pat. No. US 6607598 Continuation-in-part of Ser. No. US 2000-551614, filed on 17 Apr 2000, GRANTED, Pat. No. US 6368658 Continuation-in-part of Ser. No. US 1999-293994, filed on 19 Apr 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	1271		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention has several plausible embodiments. In one embodiment an apparatus for coating a medical device is provided. This apparatus includes a coating chamber, a vibrating structure within the coating chamber the vibrating structure capable of suspending a medical device positioned in the coating chamber, and a coating source, the coating source positioned to introduce coating into the coating chamber. In another embodiment a method of coating a medical device is provided. This method includes moving a medical device into a predetermined coating area, vibrating a structure below the medical device, the vibration of the structure forcing the medical device away from the vibrating structure, and coating at least a portion of the medical device that has moved away from the vibrating structure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 3 OF 19 USPATFULL on STN
ACCESSION NUMBER: 2004:64745 USPATFULL
TITLE: ePTFE crimped graft
INVENTOR(S): Sowinski, Krzysztof, Wallington, NJ, UNITED STATES
Henderson, Jamie S., Oakland, NJ, UNITED STATES
PATENT ASSIGNEE(S): SCIMED Life Systems, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049264	A1	20040311
APPLICATION INFO.:	US 2002-236261	A1	20020906 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOFFMANN & BARON, LLP, 6900 JERICHO TURNPIKE, SYOSSET, NY, 11791		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	538		

AB The present invention provides an expanded tubular graft formed of expanded polytetrafluoroethylene (ePTFE). The graft has first and second open ends and a surface longitudinally extending between the ends. The graft also includes an inner and outer cylindrical walls, where the walls have crimps located along the surface of the graft. Additionally, the graft is coated with biocompatible elastomer covering portions of the outer cylindrical walls of the PTFE graft. The resulting ePTFE crimped graft exhibits various enhanced properties, such as adjustable graft length, high kink resistance, improved suture retention and high

crush resistance as compared to the same graft without the crimps.

L24 ANSWER 4 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2004:45343 USPATFULL
TITLE: Microarray **drug delivery** coatings
INVENTOR(S): Boulais, Dennis R., Danielson, CT, UNITED STATES
Palasis, Maria, Wellesley, MA, UNITED STATES
Epstein, Samuel, Newton, MA, UNITED STATES
Naimark, Wendy, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004034337	A1	20040219
APPLICATION INFO.:	US 2002-219668	A1	20020816 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	533		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to microarray polymeric barriers designed to control the release rate of therapeutic agents. By varying the thickness of the coating or affecting, physically and/or chemically, the constituents of the barrier composition, the release profile of the underlying therapeutic agent can be modified and controlled.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 5 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2004:32306 USPATFULL
TITLE: Thermoplastic fluoropolymer-coated medical devices
INVENTOR(S): Chang, James W., Flagstaff, AZ, UNITED STATES
Cleek, Robert L., Flagstaff, AZ, UNITED STATES
Cully, Edward H., Flagstaff, AZ, UNITED STATES
Vonesh, Michael J., Flagstaff, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004024448	A1	20040205
APPLICATION INFO.:	US 2002-213126	A1	20020805 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	W. L. Gore & Associates, Inc., 551 Paper Mill Road, P.O. Box 9206, Newark, DE, 19714-9206		
NUMBER OF CLAIMS:	108		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Page(s)		
LINE COUNT:	1975		

AB A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered "functionally transparent" because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be

provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used. The desirable mechanical characteristics are surprising given the absence of cross-linking monomers and curing agents that would otherwise render such materials inadequately biocompatible. The perfluoroalkylvinylether may be perfluoromethylvinylether, perfluoroethylvinylether or perfluoropropylvinylether.

L24 ANSWER 6 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2004:24489 USPATFULL
TITLE: Delayed release dosage forms
INVENTOR(S): Wynn, David, Abington, PA, UNITED STATES
Parikh, Narendra, Long Valley, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018327	A1	20040129
APPLICATION INFO.:	US 2003-393765	A1	20030321 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US31129, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31117, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31062, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31024, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31163, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2001-966939, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966509, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966497, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-967414, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966450, filed on 28 Sep 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	1509		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	A dosage form comprises:		

(a) a core having an outer surface, wherein the core comprises at least one active ingredient and at least one disintegrant; and

(b) a shell comprising at least a first shell portion which resides upon at least a portion of the core outer surface, wherein the shell comprises (i) at least one water insoluble film forming polymer, and (ii) at least one water insoluble lipid, and the weight ratio of film forming polymer to lipid is in the range of about 40:60 to about 60:40. A method of providing a delayed burst release of an active ingredient from a dosage form comprises contacting the dosage form of this invention with a liquid medium such as gastrointestinal fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 7 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2003:334740 USPATFULL
TITLE: Modified release dosage form
INVENTOR(S): Sowden, Harry S., Glenside, PA, UNITED STATES
McNally, Gerard P., Berwyn, PA, UNITED STATES

Wynn, David, Abington, PA, UNITED STATES
Anderson, Oliver, Willow Grove, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235616	A1	20031225
APPLICATION INFO.:	US 2003-393871	A1	20030321 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US31129, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2001-966939, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966509, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966497, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-967414, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966450, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. WO 2002-US31117, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31062, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31024, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31163, filed on 28 Sep 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	1976		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB A modified release dosage form comprising at least one active ingredient and at least two cores surrounded by a shell is provided. The shell comprises at least one opening and provides for modified release of active ingredient upon contacting of the dosage form with a liquid medium. At least one of the cores is distal from the opening. In a preferred embodiment, the dosage form has a pulsatile release profile.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 8 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2003:329872 USPATFULL
TITLE: Modified release dosage form
INVENTOR(S): Wynn, David, Abington, PA, UNITED STATES
McNally, Gerard P., Berwyn, PA, UNITED STATES
Sowden, Harry S., Glenside, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232083	A1	20031218
APPLICATION INFO.:	US 2003-393752	A1	20030321 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US31129, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31117, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31062, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31024, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US31163, filed on 28 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2001-966939, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966509, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-966497, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-967414, filed on 28 Sep 2001, PENDING Continuation-in-part of Ser.		

No. US 2001-966450, filed on 28 Sep 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON &
JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1894

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a dosage form comprising at least one active ingredient, and first core and second cores surrounded by and separated by a shell. The dosage form provides a delay of at least one hour between the initial release of active ingredient contained in said first core and the initial release of active ingredient contained in said second core after contacting of the dosage form with a liquid medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 9 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2003:258639 USPATFULL
TITLE: 207 human secreted proteins
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Fan, Ping, Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)

US 1997-48880P	19970606 (60)
US 1997-48896P	19970606 (60)
US 1997-49020P	19970606 (60)
US 1997-48876P	19970606 (60)
US 1997-48895P	19970606 (60)
US 1997-48884P	19970606 (60)
US 1997-48894P	19970606 (60)
US 1997-48971P	19970606 (60)
US 1997-48964P	19970606 (60)
US 1997-48882P	19970606 (60)
US 1997-48899P	19970606 (60)
US 1997-48893P	19970606 (60)
US 1997-48900P	19970606 (60)
US 1997-48901P	19970606 (60)
US 1997-48892P	19970606 (60)
US 1997-48915P	19970606 (60)
US 1997-49019P	19970606 (60)
US 1997-48970P	19970606 (60)
US 1997-48972P	19970606 (60)
US 1997-48916P	19970606 (60)
US 1997-49373P	19970606 (60)
US 1997-48875P	19970606 (60)
US 1997-49374P	19970606 (60)
US 1997-48917P	19970606 (60)
US 1997-48949P	19970606 (60)
US 1997-48974P	19970606 (60)
US 1997-48883P	19970606 (60)
US 1997-48897P	19970606 (60)
US 1997-48898P	19970606 (60)
US 1997-48962P	19970606 (60)
US 1997-48963P	19970606 (60)
US 1997-48877P	19970606 (60)
US 1997-48878P	19970606 (60)
US 1997-57645P	19970905 (60)
US 1997-57642P	19970905 (60)
US 1997-57668P	19970905 (60)
US 1997-57635P	19970905 (60)
US 1997-57627P	19970905 (60)
US 1997-57667P	19970905 (60)
US 1997-57666P	19970905 (60)
US 1997-57764P	19970905 (60)
US 1997-57643P	19970905 (60)
US 1997-57769P	19970905 (60)
US 1997-57763P	19970905 (60)
US 1997-57650P	19970905 (60)
US 1997-57584P	19970905 (60)
US 1997-57647P	19970905 (60)
US 1997-57661P	19970905 (60)
US 1997-57662P	19970905 (60)
US 1997-57646P	19970905 (60)
US 1997-57654P	19970905 (60)
US 1997-57651P	19970905 (60)
US 1997-57644P	19970905 (60)
US 1997-57765P	19970905 (60)
US 1997-57762P	19970905 (60)
US 1997-57775P	19970905 (60)
US 1997-57648P	19970905 (60)
US 1997-57774P	19970905 (60)
US 1997-57649P	19970905 (60)
US 1997-57770P	19970905 (60)
US 1997-57771P	19970905 (60)
US 1997-57761P	19970905 (60)
US 1997-57760P	19970905 (60)
US 1997-57776P	19970905 (60)
US 1997-57778P	19970905 (60)

US 1997-57629P	19970905 (60)
US 1997-57628P	19970905 (60)
US 1997-57777P	19970905 (60)
US 1997-57634P	19970905 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 23
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 10 Drawing Page(s)
 LINE COUNT: 32746
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 10 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2003:92746 USPATFULL
 TITLE: Fiber-water with added value delivery
 systems/elements/additives, addressing specific dietary
 use(s), and/or medical use(s) for humans and animals
 INVENTOR(S): Stillman, Suzanne Jaffe, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064104	A1	20030403
APPLICATION INFO.:	US 2002-244699	A1	20020916 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 204572, PENDING Continuation of Ser. No. WO 2001-US5630, filed on 22 Feb 2001, PENDING		

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: CROSBY HEAFEY ROACH & MAY, 1901 AVENUE OF THE STARS,
 SUITE 700, LOS ANGELES, CA, 90067
 NUMBER OF CLAIMS: 31
 EXEMPLARY CLAIM: 1
 LINE COUNT: 7029

AB A shelf-stable, ready to use, water-like composition for humans/animals; as an adjunct to fiber-water, and/or safe drinking water, consumed directly, tube feedings, or in the preparation/reconstitution of food(s)/beverage(s). Fortified Fiber-Water is fiber-water, with added delivery systems: Encapsulations/particles, of different size(s), shape(s), material(s), colors, non-visible, serving one or more functions: improved taste, odor-masking; controlled release applications; bio-availability of actives, avoid hygroscopicity; minimized interactions, improved thermal, oxidative, and shelf-life; decorative. Viscosity changing elements, (with one or more viscosity changing additives, with or without encapsulations, particles) to enhance delivery of active medicants/ingredients of categories: pharmaceuticals, nutraceuticals, dietary supplements, therapeutics, diagnostics, etc. Composition ensures hydration, simultaneously providing soluble fiber (fiber-water), with additives contained within

the delivery systems, having the ability to target specific health goals/needs: weight loss, diabetes, cholesterol/heart, gastrointestinal tract disorders/improvement, osteoporosis, cancer, pain, stress, relaxant, stimulant etc.

L24 ANSWER 11 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2003:72333 USPATFULL

TITLE: Combinatorial type controlled release **drug delivery** device

INVENTOR(S): Odidi, Isa, Toronto, CANADA
Odidi, Amina, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003050620	A1	20030313
APPLICATION INFO.:	US 2001-947464	A1	20010907 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Dr. Lola A. Bartoszewicz, Sim & McBurney, 6th Floor, 330 University Avenue, Toronto, ON, M5G 1R7		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	556		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is a controlled release delivery device. The device comprises more than one vehicle comprising up to 60% by wgt active agent; up to 60% by wgt amino acid; up to 60% by wgt buffer, and up to 70% by wgt polymer. The vehicle(s) are provided within a housing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 12 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:235144 USPATFULL

TITLE: Mechanical and acoustical suspension coating of medical **implants**

INVENTOR(S): Schwarz, Marlene C., Auburndale, MA, UNITED STATES
Tocker, Stanley, Wilmington, DE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127327	A1	20020912
	US 6730349	B2	20040504
APPLICATION INFO.:	US 2002-84868	A1	20020301 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-804040, filed on 13 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-551614, filed on 17 Apr 2000, GRANTED, Pat. No. US 6368658 Continuation-in-part of Ser. No. US 1999-293994, filed on 19 Apr 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	1271		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention has several plausible embodiments. In one embodiment an apparatus for coating a medical device is provided. This apparatus includes a coating chamber, a vibrating structure within the coating chamber the vibrating structure capable of suspending a medical device positioned in the coating chamber, and a coating source, the coating source positioned to introduce coating into the coating chamber.

In another embodiment a method of coating a medical device is provided. This method includes moving a medical device into a predetermined coating area, vibrating a structure below the medical device, the vibration of the structure forcing the medical device away from the vibrating structure, and coating at least a portion of the medical device that has moved away from the vibrating structure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 13 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:198365 USPATFULL

TITLE: Methods for coating particles and particles produced thereby

INVENTOR(S): Talton, James D., Gainesville, FL, UNITED STATES

PATENT ASSIGNEE(S): Nanosphere, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106461	A1	20020808
APPLICATION INFO.:	US 2002-95585	A1	20020313 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-588208, filed on 6 Jun 2000, GRANTED, Pat. No. US 6406745		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-138006P	19990607 (60)
	US 1999-137733P	19990607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT &, DUNNER LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	1833	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of coating core materials by providing target materials and core materials; ablating the target materials to form ablated particulate target materials; and coating the core materials with said ablated particulate target materials; wherein the method is performed at a pressure of about 10 Torr or higher. Methods of coating particles with nanometer to multiple nanometer thick coatings in atmospheric pressure, and using pneumatic fluidization, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 14 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:143988 USPATFULL

TITLE: Methods for coating particles and particles produced thereby

INVENTOR(S): Talton, James D., Gainesville, FL, United States

PATENT ASSIGNEE(S): Nanosphere, Inc., Alachua, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406745	B1	20020618
APPLICATION INFO.:	US 2000-588208		20000606 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137733P	19990607 (60)
	US 1999-138006P	19990607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	

PRIMARY EXAMINER: Barr, Michael
ASSISTANT EXAMINER: Blanton, Rebecca
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 1893

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of coating core materials by providing target materials and core materials; ablating the target materials to form ablated particulate target materials; and coating the core materials with said ablated particulate target materials; wherein the method is performed at a pressure of about 10 Torr or higher. Methods of coating particles with nanometer to multiple nanometer thick coatings in atmospheric pressure, and using pneumatic fluidization, are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 15 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:105712 USPATFULL
TITLE: Compositions and methods for therapeutic agents complexed with calcium phosphate and encased by casein
INVENTOR(S): Morcol, Tulin, Decatur, GA, UNITED STATES
Bell, Steve J.D., Marietta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002054914	A1	20020509
APPLICATION INFO.:	US 2001-932503	A1	20010817 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-496771, filed on 3 Feb 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-118356P	19990203 (60)
	US 1999-118364P	19990203 (60)
	US 1999-118355P	19990203 (60)
	US 2001-267357P	20010209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, SUITE 2800, ATLANTA, GA, 30309	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1243	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to an oral **drug delivery** system which incorporates a therapeutic bioactive agent with biodegradable calcium phosphate particles, the particles then encapsulated by casein. The resulting particles provide a carrier designed to protect the therapeutic agent in the harsh, acidic environment of the stomach before releasing the agent into the small intestine. The therapeutic agent may be any therapeutically effective agent, such as a natural isolate or synthetic chemical or biological agent, such as a therapeutic agent, and in particular, may be a protein or a peptide such as insulin. Also incorporated with the particles may be additional surface modifying agents to assist binding, controlled release, or to otherwise modify the particles. The particles generally support the therapeutic agent to form controlled- or sustained-release particles for the oral or mucosal delivery of the therapeutic agent over time, wherein the therapeutic agent is incorporated into the structure of the particle core, disposed on the surface of the particle, or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 16 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:75070 USPATFULL
TITLE: Coating medical devices using air suspension
INVENTOR(S): Schwarz, Marlene, Newton, MA, United States
Miller, Kathleen, Shrewsbury, MA, United States
Kamath, Kalpana, Natick, MA, United States
PATENT ASSIGNEE(S): Scimed Life Systems, Inc., Maple Grove, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6368658	B1	20020409
APPLICATION INFO.:	US 2000-551614		20000417 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-293994, filed on 19 Apr 1999, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Parker, Fred J.		
ASSISTANT EXAMINER:	Michener, Jennifer Kolb		
LEGAL REPRESENTATIVE:	Kenyon & Kenyon		
NUMBER OF CLAIMS:	44		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1195		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and apparatuses for coating medical devices and the devices thereby produced are disclosed. In one embodiment, the invention includes a method comprising the steps of suspending the medical device in an air stream and introducing a coating material into the air stream such that the coating material is dispersed therein and coats at least a portion of the medical device. In another embodiment, the medical devices are suspended in an air stream and a coating apparatus coats at least a portion of the medical device with a coating material. The coating apparatus may include a device that utilizes any number of alternative coating techniques for coating the medical devices. This process is used to apply one or more coating materials, simultaneously or in sequence. In certain embodiments of the invention, the coating materials include therapeutic agents, polymers, sugars, waxes, or fats. By using air suspensions to coat medical devices, the methods of the present invention result in coatings having minimal defects and uniform thicknesses and mechanical properties. Further, the methods of the present invention are time efficient and cost effective because they facilitate the coating of numerous medical devices in a single batch, resulting in numerous medical device units containing substantially the same coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 17 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:70537 USPATFULL
TITLE: Method and apparatus for attaching tags to medical and non-medical devices
INVENTOR(S): Ishikawa, Akira, Royce City, TX, United States
Takeda, Nabuo, Richardson, TX, United States
Ahn, Suzanne I., Dallas, TX, United States
Hays, Steven R., Dallas, TX, United States
PATENT ASSIGNEE(S): Ball Semiconductor, Inc., Allen, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6366206	B1	20020402
APPLICATION INFO.:	US 2000-586077		20000602 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137100P	19990602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wu, Daniel J.	
ASSISTANT EXAMINER:	Nguyen, Tai T.	
LEGAL REPRESENTATIVE:	Howison, Chauza, Thoma, Handley & Arnott, L.L.P.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	807	

AB A method and apparatus for attaching one or more transponders to medical and non-medical products to tag respective ones of the products with identifying data contained in a memory of the transponders. The one or more transponders each include a memory containing the corresponding identifying data which is emitted by the respective transponder in response to an electromagnetic signal emitted externally of the transponder. The identifying data corresponds to at least one of the respective one or more transponders and a respective product for tagging. The one or more transponders are attached to respective ones of the products to tag the products with the corresponding identifying data.

L24 ANSWER 18 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2002:21854 USPATFULL

TITLE: Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s)

INVENTOR(S): Stillman, Suzanne Jaffe, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012689	A1	20020131
APPLICATION INFO.:	US 2001-963209	A1	20010926 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US9171, filed on 21 Mar 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-192243P	20000321 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROSBY HEAFEY ROACH & MAY, 1901 AVENUE OF THE STARS, SUITE 700, LOS ANGELES, CA, 90067	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	4740	

AB Liquid activated infusion packet(s)/system, promoting hydration, containing active and/or inactive ingredients and/or a support member(s). Infusion Packet(s)/System is one or more individual compartments, and/or group(s), whereby the enveloping material(s) may be totally or partially dissolvable, edible, transparent, opaque, decorated, etc. Further, including of one or more: color(s), flavor(s), aroma(s), pharmaceutical(s), nutraceutical(s), dietary supplement(s), enzyme(s), pre/pro-biotic(s), amino-acid(s), soluble-fiber(s), diagnostic agent(s) etc. regardless of form, +/- effervescence, +/- uniform/controlled-release encapsulations into liquid for humans and/or animals. Enveloping material may be in whole and/or in combination; non-synthetic/porous, and/or synthetic porous/non-porous with deliberate perforations. Infusion Packet(s)/System +/- tag, support member for assistance, consumer compliance: promotion, advertising, education, entertainment, (toy/game), etc. Manual and/or power operated parts,

lights, noise, etc. Additionally incorporated; unique business modalities with test market opportunities and/or the ability to provide income and/or esteem for the health challenged.

L24 ANSWER 19 OF 19 USPATFULL on STN

ACCESSION NUMBER: 2001:160720 USPATFULL

TITLE: Device and method for protecting medical devices during a coating process

INVENTOR(S): Schwarz, Marlene, Newton, MA, United States
Weber, Jan, Tuam, Ireland
Hansen, Henrik, Kinvar, Ireland
Lubinsky, Paul, Blackstone, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001022988	A1	20010920
	US 6607598	B2	20030819
APPLICATION INFO.:	US 2001-804040	A1	20010313 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-551614, filed on 17 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1999-293994, filed on 19 Apr 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	1098		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and devices for protecting and/or coating medical devices are disclosed. In one embodiment, a method is disclosed that includes surrounding a medical device with a cage, the medical device having a surface. The method further includes attaching the medical device to the cage with at least one securement, suspending the medical device in an air stream, the air stream substantially devoid of suspending particles, and coating at least a portion of said surface of said suspended medical device with a first coating material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

Connection closed by remote host